NBE-Therapeutics

Research in cancer treatment.

Launch date

Apr 2012

Employees

Market cap

Enterprise valuation

AUD2.0b (Public information from Dec 2020)

Company register number CH-270.4.003.576-2

Basel Canton of Basel-Stadt (HQ)

Revenues, earnings & profits over time

EUR	2015	2016	2017	2018
Revenues	4.6m	4.7m	4.3m	4.4m
% growth	-	1 %	(8 %)	4 %

Source: Dealroom estimates

Date	Investors	Amount	Round
-	VentureLab	N/A	-
Jan 2013	Boehringer Ingelheim Venture Fund	N/A	Seed
Mar 2015	Boehringer Ingelheim Venture Fund	€2.8m	Series A
Nov 2016	PPF Group Boehringer Ingelheim Venture Fund	€18.7m	Series B
Jun 2018	PPF Group Novo Holdings Boehringer Ingelheim Venture Fund	€17.3m	Series B
Jan 2020*	PPF Group Boehringer Ingelheim Boehringer Ingelheim Venture Fund	$22.0m	Series C
Dec 2020	Boehringer Ingelheim	€1.2b Valuation: €1.2b	Acquisition
Total Funding		AUD100m

Tech stackLearn more about the technologies and tools that this company uses.

Financials